Directly Observed Therapy in HIV Infected Adolescent Focus Groups
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to help researchers use information from HIV infected adolescents to design a directly observed therapy (DOT) program that will help adolescents take their anti-HIV medications correctly.
| Condition |
|---|
|
HIV Infections |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Directly Observed Therapy (DOT) in HIV-Infected Adolescents: Part A-Focus Groups |
| Estimated Enrollment: | 30 |
| Study Start Date: | April 2004 |
| Study Completion Date: | July 2004 |
The rate of HIV infection among adolescents is increasing at an alarming rate. Adherence to antiretroviral therapy has been a major challenge in achieving and maintaining adequate control of the disease in this population. DOT has been shown effective in individuals with tuberculosis (TB), but DOT in HIV infected populations has not been thoroughly examined. This study will collect information from HIV infected adolescents in order to establish a DOT program that will increase successful adherence to HIV treatment and will benefit the public by preventing development of viral resistance and reducing the risk of transmission.
Adolescent participants in this study will be assigned to one of three 2-hour focus group sessions, each at a different site. The participants will complete a questionnaire and will give input about designing a DOT intervention model that will be accepted by adolescents. The model will then be used in a pilot study to determine the feasibility of implementing DOT programs in the community to help HIV infected adolescents.
Eligibility| Ages Eligible for Study: | 16 Years to 21 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV infected due to high-risk behavior
- Regular attendee of local adolescent HIV support group
- Current use of antiretrovirals or history of antiretroviral therapy
- Permission of parent or legal guardian if participant is less than the legal age of consent. Assent of the minor participant should be obtained where required.
Exclusion Criteria:
- Perinatal HIV infection
- Visibly distraught or emotionally unstable
- Pregnancy or breast-feeding
Contacts and Locations| United States, California | |
| Los Angeles County Medical Center/USC | |
| Los Angeles, California, United States, 90033 | |
| United States, Florida | |
| University of Miami (Pediatric) | |
| Miami, Florida, United States, 33136 | |
| United States, Tennessee | |
| St. Jude Childrens Research Hospital, Memphis | |
| Memphis, Tennessee, United States, 38105-2794 | |
| Study Chair: | Patricia Flynn, MD | St. Jude Children's Research Hospital |
More Information
Additional Information:
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00079729 History of Changes |
| Other Study ID Numbers: | PACTG P1036A, 10193 |
| Study First Received: | March 11, 2004 |
| Last Updated: | October 26, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Treatment Experienced |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on May 19, 2013